Severe Congenital Protein C Deficiency: Practical Aspects of Management

Subcutaneous (SC) protein C (PC) was used in a child with purpura fulminans secondary to severe congenital PC deficiency. For maintenance, PC 80–120 IU/kg, given over 60–90 min SC Q48hr, has been successful as a home therapy for more than 3 years. The treatment was monitored by measuring trough PC chromogenic activity (target ≥15%) and D‐dimer levels. No change in clinical course was appreciated after discontinuing enoxaparin (and leaving the patient on prophylactic PC replacement alone). A significant discrepancy between clotting‐based and chromogenic‐based PC activity is shown.

[1]  P. Monagle,et al.  Long-term Follow-up of Homozygote Protein C Deficiency After Multimodal Therapy , 2014, Journal of pediatric hematology/oncology.

[2]  P. Fiorini,et al.  Continuous subcutaneous infusion of protein C concentrate using an insulin pump in a newborn with congenital protein C deficiency. , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[3]  W. Behnisch,et al.  Subcutaneous protein C concentrate in the management of severe protein C deficiency – experience from 12 centres , 2014, British journal of haematology.

[4]  S. Pal,et al.  Protein C deficiency , 2014, Indian Journal of Hematology and Blood Transfusion.

[5]  Michael D. Green,et al.  Long‐term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  E. V. Van Cott,et al.  Advances in laboratory testing for thrombophilia , 2012, American journal of hematology.

[7]  S. Vesely,et al.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[8]  Anthony K. C. Chan,et al.  Diagnosis and management of neonatal purpura fulminans. , 2011, Seminars in fetal & neonatal medicine.

[9]  P. Brons,et al.  Long-term Subcutaneous Protein C Replacement in Neonatal Severe Protein C Deficiency , 2011, Pediatrics.

[10]  E. V. Van Cott,et al.  Laboratory tests for antithrombin deficiency , 2010, American journal of hematology.

[11]  E. V. Van Cott,et al.  Laboratory tests for protein C deficiency , 2010, American journal of hematology.

[12]  M. Albisetti,et al.  Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency , 2010, Biologics : targets & therapy.

[13]  J. Kim,et al.  Long‐term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation , 2009, Pediatric transplantation.

[14]  K. Kottke-Marchant,et al.  Laboratory issues in diagnosing abnormalities of protein C, thrombomodulin, and endothelial cell protein C receptor. , 2002, Archives of pathology & laboratory medicine.

[15]  C. Pegelow,et al.  En bloc heterotopic auxiliary liver and bilateral renal transplant in a patient with homozygous protein C deficiency. , 2001, The Journal of pediatrics.

[16]  A. Minford,et al.  Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate , 1996, British journal of haematology.

[17]  M. Dreyfus,et al.  Replacement Therapy with a Monoclonal Antibody Purified Protein C Concentrate in Newborns with Severe Congenital Protein C Deficiency , 1995, Seminars in thrombosis and hemostasis.

[18]  J. Magny,et al.  Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. , 1991, The New England journal of medicine.

[19]  R. Marlar,et al.  Hereditary Dysfunctional Protein C Molecules (Type II): Assay Characterization and Proposed Classification , 1990, Thrombosis and Haemostasis.

[20]  T. Starzl,et al.  SUCCESSFUL TREATMENT OF HOMOZYGOUS PROTEIN C DEFICIENCY BY HEPATIC TRANSPLANTATION , 1988, The Lancet.

[21]  G. Walker,et al.  ESSENTIAL DRUGS FOR PRIMARY-HEALTHCARE STANDARD PACKAGES , 1982, The Lancet.